Claims for Patent: 8,603,521

Summary for Patent: 8,603,521

Title:	Formulations of histone deacetylase inhibitor and uses thereof
Abstract:	Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
Inventor(s):	Loury; David J. (San Jose, CA), Buggy; Joseph J. (Mountain View, CA), Mody; Tarak D. (Sunnyvale, CA), Verner; Erik J. (Belmont, CA), Purro; Norbert (Los Gatos, CA), Balasubramanian; Sriram (San Carlos, CA)
Assignee:	Pharmacyclics, Inc. (Sunnyvale, CA)
Application Number:	12/761,588
Patent Claims:	1. A method of treating cancer in a human, comprising: orally administering a first dose of Compound 1, and orally administering a second dose of Compound 1 about 4 to about 6 hours after the first dose ##STR00005## wherein a plasma concentration of Compound 1 which is effective for treating cancer is maintained for at least 6 consecutive hours. 2. The method of claim 1, wherein the effective plasma concentration of Compound 1 is about 0.2 uM. 3. The method of claim 1, wherein AUC.sub.0-4h of Compound 1 is about 0.272.+-.0.051 .mu.Mh. 4. The method of claim 1, comprising orally administering a third dose of Compound 1, wherein the first dose, the second dose and the third dose are each administered 4 to 6 hours apart. 5. The method of claim 1, wherein the daily dose of Compound 1 is 2 mg/kg. 6. The method of claim 1, wherein the daily dose of is about 10 mg to about 300 mg. 7. The method of claim 1, wherein the cancer is a hematological cancer, solid tumor or a sarcoma. 8. The method of claim 1, wherein the cancer is selected from: breast cancer, colon cancer, colorectal carcinomas, non-small cell lung cancer, small-cell lung cancer, liver cancer, ovarian cancer, prostate cancer, uterine cervix cancer, urinary bladder cancer, gall bladder carcinoma, gastric carcinoma, esophageal cancer, gastrointestinal stromal tumor, pancreatic cancer, germ cell tumors, mast cell tumors, neuroblastoma, retinoblastoma, mesothelioma, mastocytosis, testicular cancers, glioblastomas, astrocytomas, sarcoma, osteosarcoma, B cell lymphoma, T cell lymphoma, NK cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, melanoma, basal cell carcinoma, skin cancer, myeloma, leukemia, acute myelocytic leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome, chronic lymphocytic leukemia (CLL) and chronic myelogenous leukemia (CML). 9. The method of claim 1, wherein the cancer is selected from: breast cancer, colon cancer, colorectal carcinomas, non-small cell lung cancer, liver cancer, ovarian cancer, uterine cervix cancer, gastric carcinoma, pancreatic cancer, glioblastomas, B cell lymphoma, T cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, myeloma, myelodysplastic syndrome (MDS). 10. The method of claim 1, further comprising administering to the human at least one additional therapy selected from anti-cancer agents, anti-emetic agents, radiation therapy, or combinations thereof. 11. The method of claim 1, further comprising administering to the human at least one additional therapeutic agent selected from: DNA-damaging agents; topoisomerase I or II inhibitors; alkylating agents; PARP inhibitors; proteasome inhibitors; RNA/DNA antimetabolites; antimitotics; immunomodulatory agents; antiangiogenics; aromatase inhibitors; hormone-modulating agents; apoptosis inducing agents; kinase inhibitors; monoclonal antibodies; or combinations thereof. 12. The method of claim 1, further comprising administering to the human at least one additional therapeutic agent selected from: abarelix; ABT-888; aldesleukin; aldesleukin; alemtuzumab; alitretinoin; allopurinol; altretamine; amifostine anastrozole; arsenic trioxide; asparaginase; azacitidine; AZD-2281; arsenic trioxide; bendamustine; bevacizumab; bexarotene; bleomycin; bortezomib; BSI-201; busulfan; busulfan; calusterone; capecitabine; carboplatin; carfilzomib; carmustine; carmustine; celecoxib; cetuximab; chlorambucil; cisplatin; cladribine; clofarabine; cyclophosphamide; cytarabine; cytarabine liposomal; dacarbazine; dactinomycin; darbepoetin alfa; dasatinib; daunorubicin liposomal; daunorubicin; decitabine; denileukin; dexrazoxane; docetaxel; doxorubicin; doxorubicin liposomal; dromostanolone propionate; epirubicin; epoetin alfa; erlotinib; estramustine; etoposide phosphate; etoposide; exemestane; filgrastim; floxuridine; fludarabine; fluorouracil; fulvestrant; gefitinib; gemcitabine; gemtuzumab ozogamicin; goserelin acetate; histrelin acetate; hydroxyurea; Ibritumomab tiuxetan; idarubicin; ifosfamide; imatinib mesylate; interferon alfa 2a; Interferon alfa-2b; irinotecan; lenalidomide; letrozole; leucovorin; leuprolide Acetate; levamisole; lomustine; meclorethamine; megestrol acetate; melphalan; mercaptopurine; methotrexate; methoxsalen; mitomycin C; mitomycin C; mitotane; mitoxantrone; nandrolone phenpropionate; nelarabine; NPI-0052; nofetumomab; oprelvekin; oxaliplatin; paclitaxel; paclitaxel protein-bound particles; palifermin; pamidronate; panitumumab; pegademase; pegaspargase; pegfilgrastim; pemetrexed disodium; pentostatin; pipobroman; plicamycin, mithramycin; porfimer sodium; procarbazine; quinacrine; RAD001; rasburicase; rituximab; sargramostim; Sargramostim; sorafenib; streptozocin; sunitinib malate; tamoxifen; temozolomide; teniposide; testolactone; thalidomide; thioguanine; thiotepa; topotecan; toremifene; tositumomab; tositumomab/I-131 tositumomab; trastuzumab; tretinoin; uracil Mustard; valrubicin; vinblastine; vincristine; vinorelbine;vorinostat; zoledronate; zoledronic acid; vandetanib; lapatinib; nilotinib; axitinib; or combinations thereof. 13. The method of claim 1, further comprising administering to the human at least one additional therapeutic agent selected from: azacitidine; bendamustine; bevacizumab; bleomycin; bortezomib; carboplatin; chlorambucil; cisplatin; cyclophosphamide; cytarabine; dacarbazine; darbepoetin alfa; daunorubicin liposomal; daunorubicin; decitabine; docetaxel; doxorubicin; doxorubicin liposomal; epirubicin; epoetin alfa; erlotinib; etoposide; fludarabine; fluorouracil; gemcitabine; Ibritumomab tiuxetan; irinotecan; lenalidomide; leucovorin; melphalan; methotrexate; oxaliplatin; paclitaxel; paclitaxel protein-bound particles; pemetrexed disodium; pentostatin; RAD001; rituximab; sorafenib; sunitinib malate; tamoxifen; temozolomide; topotecan; tositumomab; tositumomab/I-131 tositumomab; trastuzumab; vincristine; vinorelbine; or combinations thereof.

Details for Patent 8,603,521

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2029-04-17
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2029-04-17
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2029-04-17
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2029-04-17
Amgen, Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234	06/01/1989		2029-04-17
Amgen, Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234			2029-04-17
Amgen, Inc.	PROCRIT	epoetin alfa	Injection	103234			2029-04-17